Gutenberg Open Science: Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer : a systematic literature review and pooled analysis

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8799

Full metadata record

DC Field	Value	Language
dc.contributor.author	Karampinis, Ioannis	-
dc.contributor.author	Dionysopoulou, Anna	-
dc.contributor.author	Galata, Christian	-
dc.contributor.author	Almstedt, Katrin	-
dc.contributor.author	Grilli, Maurizio	-
dc.contributor.author	Hasenburg, Annette	-
dc.contributor.author	Roessner, Erich D.	-
dc.date.accessioned	2023-02-10T10:03:45Z	-
dc.date.available	2023-02-10T10:03:45Z	-
dc.date.issued	2022	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/8815	-
dc.description.abstract	Objectives Breast and ovarian cancer account for over 30% of malignant pleural effusions (MPEs). Treatment of the metastatic disease requires control of the MPE. Even though primarily symptomatic, the treatment of the MPE can potentially affect the oncological course of the disease. The aim of this review is to analyze the effectiveness of intrathoracic chemotherapy in the treatment of MPE caused by breast and ovarian cancer. Methods A systematic literature research was conducted up until May 2021. Studies published in English on patients undergoing either surgical or interventional intrapleural chemotherapy were included. Results Thirteen studies with a total of 497 patients were included. Analysis was performed on 169 patients with MPE due to breast cancer and eight patients with MPE secondary to ovarian cancer. The pooled success rates of intrathoracic chemotherapy for controlling the MPE were 59.1% and 87.5%, respectively. A survival analysis was not possible with the available data. The overall toxicity of the treatment was low. Conclusions Intrathoracic chemotherapy achieves symptomatic control of the MPE in 59.1% of patients with metastatic breast cancer and 87.5% of patients with metastatic ovarian cancer. This is inferior to other forms of surgical pleurodesis. Data from small case series and studies on intraperitoneal chemotherapy show promising results. However, formal oncological studies on the use of intrathoracic chemotherapy for metastatic breast or ovarian cancer are lacking. Further prospective pilot studies are needed to assess the therapeutic oncological effects of this treatment.	en_GB
dc.description.sponsorship	Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577	de
dc.language.iso	eng	de
dc.rights	CC BY	*
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer : a systematic literature review and pooled analysis	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-8799	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Thoracic cancer	de
jgu.journal.volume	13	de
jgu.journal.issue	7	de
jgu.pages.start	883	de
jgu.pages.end	888	de
jgu.publisher.year	2022	-
jgu.publisher.name	Wiley-Blackwell	de
jgu.publisher.place	Hoboken, NJ u.a.	de
jgu.publisher.issn	1759-7714	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1111/1759-7714.14361	de
jgu.organisation.ror	https://ror.org/023b0x485	-
jgu.subject.dfg	Lebenswissenschaften	de
Appears in collections:	DFG-491381577-G

Files in This Item:

	File	Description	Size	Format
	hyperthermic_intrathoracic_ch-20230210110047772.pdf		717.28 kB	Adobe PDF	View/Open

Show simple item record